Incyte (INCY) reported third-quarter 2026 total GAAP revenue of $1.56 billion, up 14% from a year earlier. The company posted a GAAP net loss of $784.8 million, or $3.86 per basic and diluted share, driven in part by a $1.23 billion in-process research and development expense related to its Vega Therapeutics acquisition.
Total net sales rose 14% to $1.32 billion. Incyte raised its 2026 guidance for total net sales, Opzelura sales and Hematology and Oncology sales.
- Jakafi and Jakafi XR net sales increased 4% to $827 million.
- Opzelura net sales rose 36% to $255 million.
- Hematology and Oncology portfolio net sales increased 38% to $235 million.
- 2026 total net-sales guidance was raised to $5.21 billion to $5.30 billion, from $5.13 billion to $5.26 billion previously.
- Cash, cash equivalents and marketable securities totaled $3.9 billion as of September 30, 2026.
$INCY Insider Trading Activity
$INCY insiders have traded $INCY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $INCY stock by insiders over the last 6 months:
- PABLO J CAGNONI (President, Global Head of R&D) has made 0 purchases and 6 sales selling 58,104 shares for an estimated $7,053,796.
- STEVEN H STEIN (CMO & Head of Late-Stage Dev.) has made 0 purchases and 2 sales selling 30,114 shares for an estimated $3,407,541.
- THOMAS TRAY (Principal Accounting Officer) has made 0 purchases and 2 sales selling 4,690 shares for an estimated $463,564.
- PATRICK A MAYES (EVP & Chief Scientific Officer) sold 2,207 shares for an estimated $273,645
- MOHAMED KHAIRIE ISSA (EVP, Head of U.S. Commercial) sold 1,093 shares for an estimated $125,705
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$INCY Hedge Fund Activity
We have seen 492 institutional investors add shares of $INCY stock to their portfolio, and 338 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LOS ANGELES CAPITAL MANAGEMENT LLC removed 1,709,888 shares (-74.7%) from their portfolio in Q2 2026, for an estimated $193,832,903
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,692,439 shares (+inf%) to their portfolio in Q2 2026, for an estimated $191,854,885
- TWO SIGMA INVESTMENTS, LP added 1,587,645 shares (+381.7%) to their portfolio in Q2 2026, for an estimated $179,975,437
- PACER ADVISORS, INC. added 1,431,426 shares (+inf%) to their portfolio in Q2 2026, for an estimated $162,266,451
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 986,204 shares (-57.4%) from their portfolio in Q2 2026, for an estimated $111,796,085
- BLACKROCK, INC. removed 945,480 shares (-5.0%) from their portfolio in Q2 2026, for an estimated $107,179,612
- JPMORGAN CHASE & CO added 761,690 shares (+inf%) to their portfolio in Q2 2026, for an estimated $86,345,178
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
